-
*Noriko Okahashi
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Dainippon Sumitomo Pharma Co., Ltd.
-
Takashi Ikeda
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association ASKA Pharmaceutical Co., Ltd.
-
Shuichi Kai
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Bristol-Myers K.K.
-
Shinichi Komatsu
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association GlaxoSmithKline K.K.
-
Hajime Matsui
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association The Chemo-Sero-Therapeutic Research Institute
-
Yasuhiro Yamashita
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Nippon Shinyaku Co., Ltd.
-
Keiji Yamamoto
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Takeda Pharmaceutical Co., Ltd.
-
Fumio Sagami
ICH-M3 Task Force (DART Sub-working Group), Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures Association Eisai Co., Ltd.
